Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Atrial fibrillation: Anticoagulation for AF: can we GRASP-AF patients?

× No keyword cloud information.

9 in total

1. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association.

Authors: A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof
Journal: Eur Heart J Date: 2012-08-24 Impact factor: 29.983

2. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.

Authors: Jonas Bjerring Olesen; Christian Torp-Pedersen; Morten Lock Hansen; Gregory Y H Lip
Journal: Thromb Haemost Date: 2012-04-03 Impact factor: 5.249

3. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients.

Authors: Thomas Wilke; Antje Groth; Sabrina Mueller; Matthias Pfannkuche; Frank Verheyen; Roland Linder; Ulf Maywald; Thomas Kohlmann; You-Shan Feng; Günter Breithardt; Rupert Bauersachs
Journal: Thromb Haemost Date: 2012-03-08 Impact factor: 5.249

4. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.

Authors: Amitava Banerjee; Deirdre A Lane; Christian Torp-Pedersen; Gregory Y H Lip
Journal: Thromb Haemost Date: 2011-12-21 Impact factor: 5.249

5. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.

Authors: Jonas Bjerring Olesen; Gregory Y H Lip; Jesper Lindhardsen; Deirdre A Lane; Ole Ahlehoff; Morten Lock Hansen; Jakob Raunsø; Janne Schurmann Tolstrup; Peter Riis Hansen; Gunnar Hilmar Gislason; Christian Torp-Pedersen
Journal: Thromb Haemost Date: 2011-07-20 Impact factor: 5.249

6. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.

Authors: Gregory Y H Lip; Robby Nieuwlaat; Ron Pisters; Deirdre A Lane; Harry J G M Crijns
Journal: Chest Date: 2009-09-17 Impact factor: 9.410

7. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.

Authors: Ron Pisters; Robby Nieuwlaat; Deirdre A Lane; Harry J G M Crijns; Gregory Y H Lip
Journal: Thromb Haemost Date: 2012-11-22 Impact factor: 5.249

8. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.

Authors: Jonathan Mant; F D Richard Hobbs; Kate Fletcher; Andrea Roalfe; David Fitzmaurice; Gregory Y H Lip; Ellen Murray
Journal: Lancet Date: 2007-08-11 Impact factor: 79.321

9. The use of anticoagulants in the management of atrial fibrillation among general practices in England.

Authors: Campbell Cowan; Richard Healicon; Ian Robson; W Robert Long; James Barrett; Matthew Fay; Keith Tyndall; Chris P Gale
Journal: Heart Date: 2013-02-07 Impact factor: 5.994

9 in total